イピリムマブ＋ニボルマブの新興薬剤に関する洞察と市場予測：2032年

イピリムマブYERVOYは、ヒト細胞傷害性Tリンパ球抗原4（CTLA-4）阻害抗体であり、切除不能な悪性胸膜中皮腫（MPM）の成人患者を対象に、ニボルマブとの併用によるファーストライン治療が適応とされています。

2020年4月、BMSは、前治療歴のないMPMを対象にOPDIVOとYERVOYの併用療法を評価する重要な第III相試験であるCheckMate743試験（NCT02899299）が、主要評価項目である全生存期間（OS）を達成したと発表しました。独立データモニタリング委員会が実施した事前に規定された中間解析によると、OPDIVOとYERVOYの併用は、化学療法（ペメトレキセドとシスプラチンまたはカルボプラチン）と比較して、統計学的に有意かつ臨床的に意義のあるOSの改善をもたらしました。

当レポートでは、主要7ヶ国におけるイピリムマブ＋ニボルマブ市場について調査し、市場の概要とともに、2023年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 悪性胸膜中皮腫（MPM）に対するイピリムマブ＋ニボルマブの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• 規制上のマイルストーン
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 イピリムマブ＋ニボルマブの市場評価

• 悪性胸膜中皮腫（MPM）に対するイピリムマブ+ニボルマブの市場展望
• 主要7ヶ国市場分析
  • 主要7ヶ国における悪性胸膜中皮腫（MPM）に対するイピリムマブ+ニボルマブの市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: Ipilimumab + nivolumab, Clinical Trial Description, 2023
• Table 2: Ipilimumab + nivolumab, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: Ipilimumab + nivolumab Market Size in the 7MM, in USD million (2019-2032)
• Table 6: Ipilimumab + nivolumab Market Size in the US, in USD million (2019-2032)
• Table 7: Ipilimumab + nivolumab Market Size in Germany, in USD million (2019-2032)
• Table 8: Ipilimumab + nivolumab Market Size in France, in USD million (2019-2032)
• Table 9: Ipilimumab + nivolumab Market Size in Italy, in USD million (2019-2032)
• Table 10: Ipilimumab + nivolumab Market Size in Spain, in USD million (2019-2032)
• Table 11: Ipilimumab + nivolumab Market Size in the UK, in USD million (2019-2032)
• Table 12: Ipilimumab + nivolumab Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: Ipilimumab + nivolumab Market Size in the 7MM, USD million (2019-2032)
• Figure 2: Ipilimumab + nivolumab Market Size in the United States, USD million (2019-2032)
• Figure 3: Ipilimumab + nivolumab Market Size in Germany, USD million (2019-2032)
• Figure 4: Ipilimumab + nivolumab Market Size in France, USD million (2019-2032)
• Figure 5: Ipilimumab + nivolumab Market Size in Italy, USD million (2019-2032)
• Figure 6: Ipilimumab + nivolumab Market Size in Spain, USD million (2019-2032)
• Figure 7: Ipilimumab + nivolumab Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: Ipilimumab + nivolumab Market Size in Japan, USD million (2019-2032)

“"Ipilimumab + nivolumab Drug Insight and Market Forecast - 2032" report provides comprehensive insights about Ipilimumab + nivolumab for malignant pleural mesothelioma (MPM) in the seven major markets. A detailed picture of the Ipilimumab + nivolumab for MPM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the Ipilimumab + nivolumab for MPM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Ipilimumab + nivolumab market forecast analysis for MPM in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in MPM.

Drug Summary:

Ipilimumab YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for treating adult patients with unresectable MPM as first-line treatment in combination with nivolumab.

In April 2020, BMS announced that CheckMate743 (NCT02899299), a pivotal Phase III trial evaluating OPDIVO in combination with YERVOY in previously untreated MPM, met its primary endpoint of overall survival (OS). Based on a pre-specified interim analysis conducted by the independent Data Monitoring Committee, OPDIVO combined with YERVOY resulted in a statistically significant and clinically meaningful improvement in OS compared to chemotherapy (pemetrexed and cisplatin or carboplatin).

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the Ipilimumab + nivolumab description, mechanism of action, dosage and administration, research and development activities in malignant pleural mesothelioma (MPM).
• Elaborated details on Ipilimumab + nivolumab regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Ipilimumab + nivolumab research and development activities in MPM across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Ipilimumab + nivolumab.
• The report contains forecasted sales of Ipilimumab + nivolumab for MPM till 2032.
• Comprehensive coverage of the late-stage emerging therapies for MPM.
• The report also features the SWOT analysis with analyst views for Ipilimumab + nivolumab in MPM.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Ipilimumab + nivolumab Analytical Perspective by DelveInsight

• In-depth Ipilimumab + nivolumab Market Assessment

This report provides a detailed market assessment of Ipilimumab + nivolumab for malignant pleural mesothelioma (MPM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

• Ipilimumab + nivolumab Clinical Assessment

The report provides the clinical trials information of Ipilimumab + nivolumab for MPM covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for malignant pleural mesothelioma (MPM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Ipilimumab + nivolumab dominance.
• Other emerging products for MPM are expected to give tough market competition to Ipilimumab + nivolumab and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Ipilimumab + nivolumab in MPM.
• Our in-depth analysis of the forecasted sales data of Ipilimumab + nivolumab from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Ipilimumab + nivolumab in MPM.

Key Questions

• What is the product type, route of administration and mechanism of action of Ipilimumab + nivolumab?
• What is the clinical trial status of the study related to Ipilimumab + nivolumab in malignant pleural mesothelioma (MPM) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Ipilimumab + nivolumab development?
• What are the key designations that have been granted to Ipilimumab + nivolumab for MPM?
• What is the forecasted market scenario of Ipilimumab + nivolumab for MPM?
• What are the forecasted sales of Ipilimumab + nivolumab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to Ipilimumab + nivolumab for MPM?
• Which are the late-stage emerging therapies under development for the treatment of MPM?

Table of Contents

1. Report Introduction

2. Ipilimumab + nivolumab Overview in MPM

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestone
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Ipilimumab + nivolumab Market Assessment

• 5.1. Market Outlook of Ipilimumab + nivolumab in MPM
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Ipilimumab + nivolumab in the 7MM for MPM
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Ipilimumab + nivolumab in the United States for MPM
  • 5.3.2. Market Size of Ipilimumab + nivolumab in Germany for MPM
  • 5.3.3. Market Size of Ipilimumab + nivolumab in France for MPM
  • 5.3.4. Market Size of Ipilimumab + nivolumab in Italy for MPM
  • 5.3.5. Market Size of Ipilimumab + nivolumab in Spain for MPM
  • 5.3.6. Market Size of Ipilimumab + nivolumab in the United Kingdom for MPM
  • 5.3.7. Market Size of Ipilimumab + nivolumab in Japan for MPM

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options